Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer

Table 1 Clinicopathological characteristics of patients in the two groups, n (%)

Variables	Total (n = 115)	Control group (n = 56)	RH-endostatin group (n = 59)	χ2	P value
Sex				0.045	0.832
Male	73 (63.5)	35 (62.5)	38 (64.4)
Female	42 (36.5)	21 (37.5)	21 (35.6)
Age (59.4 ± 10.2 years)				0.475	0.491
≤ 60	64 (55.7)	33 (58.9)	31 (52.5)
> 60	51 (44.3)	23 (41.1)	28 (47.5)
Location of tumor				0.036	0.982
Lower 1/3	37 (32.2)	18 (32.2)	19 (32.2)
Middle 1/3	32 (27.8)	16 (28.5)	16 (27.1)
Upper 1/3	46 (40.0)	22 (39.3)	24 (40.7)
Degree of differentiation				0.141	0.707
Well/moderate	41 (35.7)	19 (34.0)	22 (37.3)
Poor	74 (64.3)	37 (66.0)	37 (62.7)
Amount of ascites				1.173	0.556
Small	17 (14.8)	7 (12.5)	10 (16.9)
Moderate	34 (29.6)	15 (26.8)	19 (32.2)
Massive	64 (55.6)	34 (60.7)	30 (50.8)
Peritoneal metastases				1.794	0.180
Oligo	21 (18.3)	13 (23.2)	8 (13.6)
Multiple	94 (81.7)	43 (76.8)	51 (86.4)

RH-endostatin: Recombinant human endostatin.